Cornerstone Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-223,500
| Closed | -$12.1M | – | 109 |
|
|
2025
Q4 | $12.1M | Hold |
223,500
| – | – | 0.4% | 73 |
|
|
2025
Q3 | $10.1M | Sell |
223,500
-3,500
| -2% | -$163K | 0.33% | 76 |
|
|
2025
Q2 | $10.5M | Buy |
227,000
+127,600
| +128% | +$6.26M | 0.36% | 76 |
|
|
2025
Q1 | $6.06M | Hold |
99,400
| – | – | 0.26% | 97 |
|
|
2024
Q4 | $5.62M | Hold |
99,400
| – | – | 0.22% | 102 |
|
|
2024
Q3 | $5.14M | Hold |
99,400
| – | – | 0.2% | 118 |
|
|
2024
Q2 | $4.13M | Sell |
99,400
-1,000
| -1% | -$44.7K | 0.17% | 129 |
|
|
2024
Q1 | $5.44M | Hold |
100,400
| – | – | 0.23% | 115 |
|
|
2023
Q4 | $5.15M | Sell |
100,400
-35,100
| -26% | -$1.84M | 0.23% | 114 |
|
|
2023
Q3 | $7.86M | Sell |
135,500
-54,900
| -29% | -$3.36M | 0.37% | 69 |
|
|
2023
Q2 | $12.2M | Sell |
190,400
-127,100
| -40% | -$8.52M | 0.58% | 43 |
|
|
2023
Q1 | $22M | Hold |
317,500
| – | – | 1.02% | 24 |
|
|
2022
Q4 | $22.8M | Hold |
317,500
| – | – | 1.13% | 20 |
|
|
2022
Q3 | $22.6M | Buy |
317,500
+30,000
| +10% | +$2.18M | 1.11% | 18 |
|
|
2022
Q2 | $22.1M | Buy |
287,500
+104,500
| +57% | +$7.96M | 1.16% | 15 |
|
|
2022
Q1 | $13.4M | Hold |
183,000
| – | – | 0.79% | 29 |
|
|
2021
Q4 | $11.4M | Hold |
183,000
| – | – | 0.62% | 46 |
|
|
2021
Q3 | $10.8M | Hold |
183,000
| – | – | 0.63% | 45 |
|
|
2021
Q2 | $12.2M | Buy |
183,000
+135,000
| +281% | +$8.8M | 0.72% | 40 |
|
|
2021
Q1 | $3.03M | Hold |
48,000
| – | – | 0.27% | 94 |
|
|
2020
Q4 | $2.98M | Buy |
+48,000
| New | +$2.95M | 0.26% | 91 |
|
|
2019
Q1 | – | Sell |
-50,000
| Closed | -$2.6M | – | 200 |
|
|
2018
Q4 | $2.6M | Sell |
50,000
-28,000
| -36% | -$1.5M | 0.23% | 115 |
|
|
2018
Q3 | $4.84M | Buy |
+78,000
| New | +$4.63M | 0.35% | 81 |
|
|
2017
Q4 | – | Sell |
-56,000
| Closed | -$3.57M | – | 238 |
|
|
2017
Q3 | $3.57M | Hold |
56,000
| – | – | 0.41% | 73 |
|
|
2017
Q2 | $3.12M | Hold |
56,000
| – | – | 0.57% | 46 |
|
|
2017
Q1 | $3.04M | Hold |
56,000
| – | – | 0.55% | 57 |
|
|
2016
Q4 | $3.27M | Buy |
56,000
+37,000
| +195% | +$2.02M | 0.6% | 47 |
|
|
2016
Q3 | $1.02M | Buy |
19,000
+11,000
| +138% | +$707K | 0.26% | 101 |
|
|
2016
Q2 | $588K | Buy |
+8,000
| New | +$565K | 0.15% | 144 |
|
|
2013
Q3 | – | Sell |
-15,000
| Closed | -$670K | – | 233 |
|
|
2013
Q2 | $670K | Buy |
+15,000
| New | +$651K | 0.26% | 113 |
|
Other funds holding BMY
VCM
VPM
Cornerstone Advisors's BMY Position: Q1 2026 in Review
Cornerstone Advisors sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 223,500 shares — an estimated $12.1M sold.
Cornerstone Advisors first reported a position in BMY in Q2 2013 and held it in 30 quarters. The position peaked at $22.8M in Q4 2022. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Cornerstone Advisors reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
- Cornerstone Advisors sold 223,500 Bristol-Myers Squibb shares in Q1 2026, an estimated $12.1M.
- Cornerstone Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 30 quarters.
- Cornerstone Advisors's Bristol-Myers Squibb position peaked at $22.8M in Q4 2022.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Cornerstone Advisors's 13F filing for Q1 2026, filed 8 May 2026.